// App-Quantinova.ai

: Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience

Researchers

Presenter

  • Taiga Nishihori

Principal Investigators

  • Ciara L. Freeman

  • Doris K. Hansen

  • Brandon J. Blue

  • Omar Alexis Castaneda Puglianini

  • Jongphil Kim

  • Ariel F. Grajales-Cruz

  • Jason Brayer

  • Jose Ochoa

  • Hien D. Liu

  • Kenneth H. Shain

  • Rachid C. Baz

  • Frederick L. Locke

  • Melissa Alsina

Medical Centers

  • Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

  • Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

  • Moffitt Cancer Center, Tampa, FL

  • Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institutte, Tampa, FL

  • Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

  • Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Solid malignancies

Biomarkers

  • Hematocrit

Drug/Treatment

  • Melphalan

Outcome

  • N/A

Study Design

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved